Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RG-101 plus GSK2878175 in treatment-naive chronic hepatitis C genotype 1 or 3
2015-004702-42Phase 2Completed
- Sponsor
- Regulus Therapeutics
- Start
- Nov 2015
- Modality
- Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of RG-101 and gsk2878175 in hepatitis C virus infection (3 arms), sponsored by Regulus Therapeutics. Primary endpoint: Proportion of subjects with sustained virologic response at 12 weeks after end of treatment. Started Nov 2015; status: completed.
02
Drugs
RG-101gsk2878175
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2015-004702-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004702-42.